About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- Metabolic syndrome is diagnosed when at least 3 of 5 features are present: abdominal obesity, high triglycerides, low HDL, hypertension, impaired fasting glucose
- It is not a single disease but a risk cluster identifying insulin resistance and cardiometabolic risk
- Management focuses on weight loss, physical activity, diet quality, BP control, lipid management, and diabetes prevention
- Metformin may be considered for diabetes prevention in high-risk prediabetes, especially younger patients with obesity or prior gestational diabetes
- ASCVD risk reduction is driven by treating each risk factor rather than treating the label alone
Overview
Metabolic syndrome describes a constellation of cardiometabolic abnormalities associated with insulin resistance and visceral adiposity. It predicts increased risk of type 2 diabetes, atherosclerotic cardiovascular disease, fatty liver disease, obstructive sleep apnea, and chronic kidney disease. The diagnosis is clinically useful because it identifies patients who need intensive lifestyle and risk-factor modification even before overt diabetes develops.
Epidemiology
Metabolic syndrome is highly prevalent in the United States and increases with age, obesity, sedentary behavior, sleep disruption, and socioeconomic risk. It is closely linked to nonalcoholic fatty liver disease, polycystic ovary syndrome, obstructive sleep apnea, and family history of type 2 diabetes. Ethnic-specific waist circumference thresholds may better capture visceral adiposity risk in some populations.
Clinical Features
Symptoms
Usually asymptomatic and identified on screening labs or vital signs
Weight gain, increased waist circumference, low exercise tolerance
Symptoms of associated conditions: snoring/daytime sleepiness, fatty liver, PCOS symptoms, acanthosis nigricans
Polyuria, polydipsia, or weight loss suggests progression to diabetes
Chest pain, dyspnea, neurologic deficits suggest ASCVD complication
Signs
Abdominal adiposity and increased waist circumference
Elevated blood pressure
Acanthosis nigricans or skin tags reflecting insulin resistance
Hepatomegaly may suggest fatty liver disease
Normal examination is common despite high metabolic risk
Investigations
First-line
Waist circumference and BMIAssess abdominal obesity and overall adiposity
Fasting lipid panelTriglycerides >=150 mg/dL and low HDL are criteria
Fasting glucose or HbA1cAssess prediabetes or diabetes
Blood pressure measurementHypertension or antihypertensive treatment is a criterion
Second-line
ALT/ASTScreen for fatty liver disease when clinically indicated
Urine albumin-to-creatinine ratioAssess kidney and cardiometabolic risk in diabetes or hypertension
10-year ASCVD risk calculationGuides statin and risk-reduction intensity
Specialist
Sleep studyIf obstructive sleep apnea symptoms are present
Endocrine evaluationIf features suggest Cushing syndrome, hypothyroidism, PCOS, or other secondary endocrine driver
1
Lifestyle foundation
- Aim for 5-10% weight loss when overweight or obese
- Mediterranean-style, DASH, or calorie-reduced eating pattern emphasizing minimally processed foods, fiber, unsaturated fats, and reduced refined carbohydrates
- At least 150 minutes/week moderate aerobic activity plus resistance training
- Sleep optimization, smoking cessation, and alcohol moderation
2
Diabetes prevention
- Treat prediabetes with intensive lifestyle intervention
- Consider metformin for high-risk prediabetes: BMI >=35, age <60, prior gestational diabetes, or rising A1c despite lifestyle
- Monitor glycemia regularly for progression
3
ASCVD risk management
- Treat hypertension to guideline targets
- Statin therapy based on ASCVD risk, diabetes status, LDL level, and age
- Address triglycerides with lifestyle first; treat severe hypertriglyceridemia to prevent pancreatitis
4
Associated conditions
- Screen and manage fatty liver disease, obstructive sleep apnea, PCOS, and chronic kidney disease when indicated
- Use anti-obesity pharmacotherapy or bariatric/metabolic surgery when criteria are met and lifestyle alone is insufficient
Complications
- Type 2 diabetes: Insulin resistance and beta-cell stress increase progression risk
- Atherosclerotic cardiovascular disease: Combined hypertension, dyslipidemia, hyperglycemia, and inflammation accelerate risk
- Fatty liver disease: Can progress to steatohepatitis, fibrosis, cirrhosis
- Obstructive sleep apnea: Worsens insulin resistance and hypertension
- Chronic kidney disease: Driven by diabetes, hypertension, and metabolic inflammation
USMLE Step 2 CK Exam Tips
- 1Metabolic syndrome requires 3 of 5: waist, triglycerides, HDL, BP, fasting glucose
- 2It is a risk cluster, not an endocrine tumor diagnosis
- 3Acanthosis nigricans is a clue to insulin resistance
- 4Prediabetes management on Step 2 CK: lifestyle first; metformin in selected high-risk patients
- 5Severe triglycerides >500 mg/dL shift priority to pancreatitis prevention
- 6Think sleep apnea in metabolic syndrome with snoring and daytime somnolence
- 7Treat the individual risk factors rather than chasing insulin levels
practicetest your knowledge on metabolic syndromeApply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — endocrine and beyond.
open q-bank